Arvinas (ARVN) Competitors

Arvinas (NASDAQ:ARVN) and Denali Therapeutics (NASDAQ:DNLI) are both medical companies, but which is the better stock? We will compare the two companies based on the strength of their dividends, community ranking, institutional ownership, risk, profitability, media sentiment, valuation, analyst recommendations and earnings.

Does the MarketBeat Community favor ARVN or DNLI?

Denali Therapeutics received 267 more outperform votes than Arvinas when rated by MarketBeat users. Likewise, 68.76% of users gave Denali Therapeutics an outperform vote while only 65.18% of users gave Arvinas an outperform vote.

Company	Underperform	Outperform
Arvinas	Outperform Votes 204 65.18%	Underperform Votes 109 34.82%
Denali Therapeutics	Outperform Votes 471 68.76%	Underperform Votes 214 31.24%

Do institutionals & insiders have more ownership in ARVN or DNLI?

95.2% of Arvinas shares are owned by institutional investors. Comparatively, 92.9% of Denali Therapeutics shares are owned by institutional investors. 4.7% of Arvinas shares are owned by company insiders. Comparatively, 12.5% of Denali Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

Which has better earnings and valuation, ARVN or DNLI?

Arvinas has higher earnings, but lower revenue than Denali Therapeutics. Arvinas is trading at a lower price-to-earnings ratio than Denali Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Arvinas	$263.40M	2.07	-$198.90M	-$0.66	-11.32
Denali Therapeutics	$330.53M	6.19	-$422.77M	-$2.67	-5.28

Do analysts recommend ARVN or DNLI?

Arvinas currently has a consensus price target of $20.29, indicating a potential upside of 171.61%. Denali Therapeutics has a consensus price target of $33.71, indicating a potential upside of 139.28%. Given Arvinas' higher probable upside, equities research analysts plainly believe Arvinas is more favorable than Denali Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Arvinas	0 Sell rating(s)	10 Hold rating(s)	12 Buy rating(s)	0 Strong Buy rating(s)	2.55
Denali Therapeutics	0 Sell rating(s)	1 Hold rating(s)	14 Buy rating(s)	2 Strong Buy rating(s)	3.06

Does the media prefer ARVN or DNLI?

In the previous week, Arvinas had 3 more articles in the media than Denali Therapeutics. MarketBeat recorded 4 mentions for Arvinas and 1 mentions for Denali Therapeutics. Denali Therapeutics' average media sentiment score of 1.58 beat Arvinas' score of 0.97 indicating that Denali Therapeutics is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Arvinas	2 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Denali Therapeutics	1 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Very Positive

Which has more volatility and risk, ARVN or DNLI?

Arvinas has a beta of 2.19, indicating that its share price is 119% more volatile than the S&P 500. Comparatively, Denali Therapeutics has a beta of 1.32, indicating that its share price is 32% more volatile than the S&P 500.

Is ARVN or DNLI more profitable?

Denali Therapeutics has a net margin of 0.00% compared to Arvinas' net margin of -10.92%. Arvinas' return on equity of -7.74% beat Denali Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Arvinas	-10.92%	-7.74%	-4.11%
Denali Therapeutics	N/A	-35.90%	-32.41%

Summary

Denali Therapeutics beats Arvinas on 11 of the 19 factors compared between the two stocks.